Türkiye Plans Local Production of Vaccines, Biosimilars and Cancer Test Kits

Türkiye's 2027 Presidential Annual Program plans to strengthen domestic production and supply security in the pharmaceutical and medical device sectors through support for vaccine and biotechnological drug projects. The goal is to boost competitiveness in global markets, reduce import dependence and ensure supply security. According to a compilation by Anadolu Agency, the leverage effect of public procurement will be used.

Strategic partnerships with the private sector will be set up to develop domestic cancer diagnostic kits and produce prototypes. Support will be given to biosimilar drugs, and financial and infrastructure support mechanisms will be created so that biotechnological drugs whose patent protection has recently expired or will soon expire can be produced in Türkiye. In the medical device sector, foreign trade volume was about $4.5 billion in 2025, with exports at $1.3 billion.

The program also cited data showing pharmaceutical production rose 12.2 percent in January-July this year compared with the same period last year. About 1.74 billion boxes were sold in the drug market in the first eight months of the year, worth 418.4 billion lira. The export-to-import coverage ratio in the medical device sector was recorded at 46 percent in the first five months of this year.